• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regenxbio Inc (NQ: RGNX )

    11.90 -0.31 (-2.54%)
    Streaming Delayed Price Updated: 2:58 PM EDT, Jun 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 556,216
    Open 12.20
    Bid (Size) 11.89 (1)
    Ask (Size) 11.91 (2)
    Prev. Close 12.21
    Today's Range 11.43 - 12.20
    52wk Range 11.56 - 28.80
    Shares Outstanding 43,466,186
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
    Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
    Via Investor's Business Daily
    Exposures Product Safety
    Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
    Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
    Via Benzinga

    Performance

    YTD
    -35.11%
    -35.11%
    1 Month
    -25.02%
    -25.02%
    3 Month
    -47.13%
    -47.13%
    6 Month
    -34.97%
    -34.97%
    1 Year
    -41.32%
    -41.32%

    More News

    Read More
    Assessing Regenxbio: Insights From 4 Financial Analysts
    Via Benzinga
    Evaluating Regenxbio: Insights From 9 Financial Analysts
    Via Benzinga
    RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Where Regenxbio Stands With Analysts
    Via Benzinga
    Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
    Via Benzinga
    Regenxbio: Q4 Earnings Insights
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    A Preview Of Regenxbio's Earnings
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
    Via The Motley Fool
    This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
    Via Benzinga
    REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
    Via Benzinga
    The One-Minute Market Report - Sunday, Feb. 11
    Via Talk Markets
    Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains'
    Via Benzinga
    Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
    Via Benzinga
    Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Why Is Gene Therapy-Focused REGENXBIO Stock Trading Higher Today?
    Via Benzinga
    Chipotle Posts Upbeat Earnings, Joins Cirrus Logic, Emerson Electric, Carlyle Group And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.